Pfizer, Regeneron CEOs see extended need for COVID-19 vaccines, treatments as pandemic enters next phase

Pharma companies with COVID-19 vaccines and drugs have reeled in big sales in recent months, but even as vaccines promise to eventually tackle the pandemic, eye-popping revenue figures will continue for quite some time, execs project.

Pfizer CEO Albert Bourla has flagged the likely need for vaccine boosters as the pandemic continues to evolve. On a recent conference call with analysts, he said that "basically all governments of the world are now discussing with us about procurement agreements" for 2022, 2023 and 2024. In fact, Europe just signed a massive agreement for up to 1.8 billion doses from Pfizer and BioNTech through 2023.